Publikationen (83) Publikationen von MARÍA ESTHER O'SHEA GAYA

2023

  1. Neurobiology of the kynurenine pathway and cannabis misuse: A new narrative

    Cannabis Use, Neurobiology, Psychology, and Treatment (Elsevier), pp. 265-278

  2. Oxidized soluble guanylyl cyclase causes erectile dysfunction in alcoholic mice

    British Journal of Pharmacology, Vol. 180, Núm. 18, pp. 2361-2376

2022

  1. Influx of kynurenine into the brain is involved in the reduction of ethanol consumption induced by Ro 61-8048 after chronic intermittent ethanol in mice

    British Journal of Pharmacology, Vol. 179, Núm. 14, pp. 3711-3726

2021

  1. Addiction and the kynurenine pathway: A new dancing couple?

    Pharmacology and Therapeutics, Vol. 223

  2. Decreased kynurenine pathway potentiate resilience to social defeat effect on cocaine reward

    Neuropharmacology, Vol. 197

  3. Increased kynurenine concentration attenuates serotonergic neurotoxicity induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats through activation of aryl hydrocarbon receptor

    Neuropharmacology, Vol. 187

2020

  1. Plasma tryptophan and kynurenine pathway metabolites in abstinent patients with alcohol use disorder and high prevalence of psychiatric comorbidity

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 102

2019

  1. Changes in brain kynurenine levels via gut microbiota and gut-barrier disruption induced by chronic ethanol exposure in mice

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 33, Núm. 11, pp. 12900-12914

  2. Serotonin is the main tryptophan metabolite associated with psychiatric comorbidity in abstinent cocaine-addicted patients

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Increasing kynurenine brain levels reduces ethanol consumption in mice by inhibiting dopamine release in nucleus accumbens

    Neuropharmacology, Vol. 135, pp. 581-591

  2. Serotonina y fármacos que actúan sobre el sistema serotoninérgico. Purinas

    Velázquez. Farmacología básica y clínica (Editorial Médica Panamericana), pp. 461-470

2017

  1. 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) produces edema due to BBB disruption induced by MMP-9 activation in rat hippocampus

    Neuropharmacology, Vol. 118, pp. 157-166

  2. Disruption of blood–brain barrier integrity in postmortem alcoholic brain: preclinical evidence of TLR4 involvement from a binge-like drinking model

    Addiction Biology, Vol. 22, Núm. 4, pp. 1103-1116

2014

  1. 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) disrupts blood-brain barrier integrity through a mechanism involving P2X7 receptors

    International Journal of Neuropsychopharmacology, Vol. 17, Núm. 8, pp. 1243-1255

  2. Current preclinical studies on neuroinflammation and changes in blood-brain barrier integrity by MDMA and methamphetamine

    Neuropharmacology, Vol. 87, pp. 125-134

  3. The JNK inhibitor, SP600125, potentiates the glial response and cell death induced by methamphetamine in the mouse striatum

    International Journal of Neuropsychopharmacology, Vol. 17, Núm. 2, pp. 235-246

2013

  1. A study on the effect of JNK inhibitor, SP600125, on the disruption of blood-brain barrier induced by methamphetamine

    Neurobiology of Disease, Vol. 50, Núm. 1, pp. 49-58

  2. Cocaine potentiates MDMA-induced oxidative stress but not dopaminergic neurotoxicity in mice: Implications for the pathogenesis of free radical-induced neurodegenerative disorders

    Psychopharmacology, Vol. 230, Núm. 1, pp. 125-135

  3. Implicación de la molécula de adhesión ALCAM en el daño cerebral. Modelo de daño neuronal mediante la administración de MDMA/éxtasis en rata

    Trauma (Spain), Vol. 24, Núm. 2, pp. 101-108

  4. Implicación de la molécula de adhesión ALCAM en el daño cerebral: modelo de daño neuronal mediante la administración de MDMA/éxtasis en rata

    Trauma, Vol. 24, Núm. 2, pp. 101-108